Renovascular disease — most often atherosclerotic renal artery stenosis — has been the subject of a clear, if initially counterintuitive, evidence base: for most patients, medical therapy is as good as opening the artery.
Medical therapy versus revascularization
The ASTRAL and CORAL trials found no clinical benefit of renal-artery angioplasty or stenting over modern medical therapy for atherosclerotic renal artery stenosis — no difference in renal function, blood pressure, cardiovascular events, or mortality — while revascularization carried real procedural risks. The 2022 American Heart Association scientific statement accordingly endorses optimal medical therapy (antihypertensives including RAAS blockers, statins, antiplatelet agents, and lifestyle change) for most patients, reserving revascularization for carefully selected cases such as rapidly declining renal function, recurrent flash pulmonary edema, or refractory hypertension — a benefit not robustly proven in trials.
Emerging mechanistic approaches
Because opening the artery does not reverse established parenchymal injury, research has turned to the kidney tissue itself. Early-phase work with autologous mesenchymal stem cells has shown improvements in renal blood flow, GFR, and inflammatory markers, and mitochondria-protective agents (elamipretide, MitoQ) and proangiogenic strategies are under study to limit ischemic and oxidative injury. These remain experimental.
| Intervention | Role | Evidence |
|---|---|---|
| Optimal medical therapy | First-line, all patients | Standard of care (ASTRAL, CORAL) |
| Revascularization (stenting) | Select high-risk only | No global benefit; procedural risk |
| Mesenchymal stem cells | Experimental | Improved blood flow/GFR in early trials |
| Mito-protective agents | Experimental | Preclinical/early clinical |
Further reading: ASTRAL (Wheatley et al., NEJM 2009); CORAL; 2022 AHA scientific statement on revascularization for renovascular disease; mesenchymal stem cell trials in renovascular disease (2020–2022).